Exact(5)
Prediction of the correct targets to combine relies on clinical experience from single target drugs, an area that should be boosted considerably by quantitative systems pharmacology, a computer-based methodology that combines preclinical neuropharmacology, neurophysiology and existing clinical information, allowing testing of combinations in a virtual human patient [110].
Our results support the clinical testing of combinations of PI3K inhibition with maximal HER2 inhibition for HER2+ breast cancer.
Therefore testing of combinations of BPs with other agents is of significant interest in the treatment of various cancers.
Thus, our results imply that a transplastomic approach for expression of recombinant proteins should include testing of combinations of different types of translation control elements for each individual foreign ORF [ 17].
The interday reproducibility across in vitro experiments was established, which enabled batch mode testing of combinations, since all combinations could not be tested in a single experiment (see Fig. S2).
Similar(55)
To accelerate the preclinical development of these combination therapies, reliable single target validation is necessary, followed by the rational selection and systematic testing of combination approaches.
Also testing of combination of several markers can be of particular importance.
The 2-agent approximation predictions, reported in the Additional file 4, can be used as a reference to prioritize further testing of combination therapy for cancer treatment.
Indeed, the testing of combination biological therapies for RA has largely been avoided for safety concerns, but targeted therapeutics may enable this in the future.
The goal is to use these lists of rare, deleterious and druggable mutations to in tumors to direct rational preclinical testing of combination therapies in cell lines and eventually treatment of patients.
These results predict that agents targeting the PI3K/Akt/mTor pathway might have anticancer activity in pancreatic cancer patients, and support the testing of combination studies involving chemotherapy or other molecular targeted agents.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.
Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com